Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis

J Neuroimmunol. 2014 Jun 15;271(1-2):56-9. doi: 10.1016/j.jneuroim.2014.04.001. Epub 2014 Apr 16.

Abstract

The levels of soluble tumor necrosis factor receptor II (sTNF-RII) were determined in serum of 161 untreated multiple sclerosis (MS) patients with different clinical forms and 46 healthy controls (HC) by ELISA. Our results show that serum sTNF-RII levels were significantly increased in patients with primary progressive MS (PPMS) compared with other MS forms and HC. Although sTNF-RII levels significantly increased over a 2-year follow-up period in a subgroup of PPMS patients, they could not discriminate between patients with and without disability progression. Additional studies are needed to further implicate sTNF-RII in patients with PPMS.

Keywords: Disability progression; Primary progressive multiple sclerosis; Tumor necrosis factor receptor II.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Analysis of Variance
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Sclerosis, Chronic Progressive / blood*
  • Multiple Sclerosis, Relapsing-Remitting
  • Receptors, Tumor Necrosis Factor, Type II / blood*

Substances

  • Receptors, Tumor Necrosis Factor, Type II